Clinical-stage biotech developing long-acting antibody drugs for inflammatory bowel disease.
Clinical-stage biotech developing long-acting antibody drugs for inflammatory bowel disease.
Moat: none (IP / patents). Pre-commercial with no approved products yet; differentiation rests on longer-acting antibody engineering.
Headquarters: Waltham, Massachusetts, United States · Founded: 2022 · Employees: 102
Size Spyre Therapeutics (SYRE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $9.64B, the 793rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $101.46 on 18 Nov 2026.
Performance Over six months the shares gained 41.1%, against +9.6% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Short interest Short interest is 12.2% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $886,000 | $2.33M |
| Revenue growth | — | — | -100% | -62% | — |
| Gross profit | $0 | $0 | $0 | -$78,000 | $365,000 |
| EBITDA | -$320M | -$220M | -$209M | -$117M | -$82.8M |
| Net income | -$253M | -$127M | -$150M | -$94.9M | -$83.8M |
| Free cash flow | n/a | n/a | -$158M | -$99.9M | -$80.2M |
| Capital expenditure | $0 | $0 | $0 | $0 | $38,000 |
| Total debt | $0 | $0 | $0 | $84.6M | $4.64M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Spyre Therapeutics SYRE | $9.64B | +41% | n/a | n/a | n/a | n/a |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 3.3× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SYRE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.0% | +5.6% | 8th highest of 21 |
| 6-month return | +41.1% | +9.6% | 6th highest of 21 |
| Distance from 52-week high | -8.3% | -11.2% | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics SYRE | United States | $9.64B | +41% | n/a | n/a | n/a | n/a | n/a |
| Pharmaron Beijing 3759.HK | Hong Kong | $9.65B | +48% | +24% | 14% | 4.4× | n/a | n/a |
| TG Therapeutics TGTX | United States | $9.99B | +66% | +69% | 21% | 11.4× | 43.0% | +426.7% |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 6.0× | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | 2.6× | -6.6% | +6.6% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 2.1× | -4.7% | +9.3% |
| Repligen RGEN | United States | $11.0B | +55% | +14% | 9% | 13.5× | 56.9% | +15.0% |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 13.6× | 17.5% | +10.0% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.25B | -7% | +9% | 3% | 0.3× | -9.7% | +7.4% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | 29.0× | n/a | n/a |
| Mankind Pharma MANKIND.NS | India | $11.6B | +5% | +13% | 21% | 7.2× | 28.6% | +18.1% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $11.6B | -4% | -19% | 19% | 9.7× | 24.9% | +6.8% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 4.7× | 27.3% | +9.4% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 7.4× | 7.3% | +12.6% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | 5.0× | 32.5% | +7.3% |
| Recordati REC.MI | Italy | $12.0B | +3% | +8% | 30% | 4.5× | 1.1% | +12.6% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $7.74B | -15% | +10% | 6% | 2.2× | 19.9% | +5.8% |
| Sbp 1177.HK | Hong Kong | $12.2B | +5% | +15% | 30% | 2.6× | -5.7% | +5.4% |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 3.4× | 17.2% | +8.7% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 2.4× | 7.1% | +7.1% |